The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic Study
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open label, prospective, two phase pharmacokinetic study. Subjects
currently attending for HIV care at St. Mary's Hospital, London will be eligible.
Phase:
Phase 1
Details
Lead Sponsor:
Imperial College London
Treatments:
Darunavir Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Maraviroc Ritonavir